Billiet Thomas, Ferrante Marc, Van Assche Gert
Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Curr Gastroenterol Rep. 2014 Nov;16(11):416. doi: 10.1007/s11894-014-0416-y.
The disease spectrum and natural course of Crohn's disease and ulcerative colitis are highly variable. The majority of Crohn's disease patients will require surgery at a certain stage in their disease compared to only a fraction of the ulcerative colitis patients. Similarly, some patients are destined to experience an indolent disease course while others will require early intensive therapy. Ideally, these subtypes of patients should be identified as early as possible with the help of reliable prognostic factors in order to guide personalized therapeutic decisions. In this review, the authors focused on the most relevant reports on the use of different prognostic factors to predict disease course, postoperative recurrence and response to therapy in patients with inflammatory bowel disease. The last 15 years have seen a wealth of novel genetic and serological markers of disease severity. Nevertheless, none of these markers have proven to be superior to careful clinical phenotyping and endoscopic features early in the disease course. Future attempts should apply an integrated approach that unites clinical, serological and (epi)genetic information with environmental influences, with a clear focus on the microbiome to ultimately identify molecular-based and clinically relevant subgroups.
克罗恩病和溃疡性结肠炎的疾病谱及自然病程具有高度变异性。与仅一小部分溃疡性结肠炎患者相比,大多数克罗恩病患者在疾病的某个阶段需要接受手术。同样,一些患者注定会经历病情进展缓慢的病程,而另一些患者则需要早期强化治疗。理想情况下,应借助可靠的预后因素尽早识别这些患者亚型,以指导个性化治疗决策。在本综述中,作者重点关注了关于使用不同预后因素预测炎症性肠病患者疾病进程、术后复发及对治疗反应的最相关报告。在过去15年里,出现了大量关于疾病严重程度的新型遗传和血清学标志物。然而,在疾病病程早期,这些标志物均未被证明优于仔细的临床表型分析和内镜特征。未来的尝试应采用一种综合方法,将临床、血清学和(表观)遗传学信息与环境影响相结合,明确聚焦于微生物组,以最终识别基于分子且具有临床相关性的亚组。